Second-Generation PD-(L)1 x VEGF Agents: Trispecifics, PD-1 x IL-2, and Follower Strategies | Oncology Modality Intelligence

Description

List of Tables

The first generation of PD-(L)1XVEGF bispecifics is not yet approved outside China, and the second generation has already begun. That is what happens when a class attracts this much capital this fast: leaders commoditize before they launch, and the strategic question shifts from whether the mechanism works to what followers do about it. The answers now in development fall into several designs. Trispecific constructs add a third arm - CStone's CS2009 layers CTLA-4 onto PD-1 and VEGF - betting that more biology in one molecule widens the therapeutic window. Cooperative and affinity-tuned constructs, from Crescent Biopharma's CR-001 to Ottimo's jankistomig, argue that geometry, not arm count, is the differentiator. And the PD-1XIL-2 family attacks the problem from the side, engineering cytokine activity that checkpoint blockade alone cannot recruit - the approach Innovent built with IBI363 and that Takeda optioned in October 2025 in a transaction that anchored the program's commercialization in Japan. Around these designs sit the first-generation incumbents' own answers: Akeso developing follow-ons to ivonescimab, BioNTech pairing BNT327 with its ADC and mRNA assets, Pfizer layering SSGJ-707 onto the Seagen antibody-drug conjugate base, and Summit pursuing ADC combinations for ivonescimab. The contested questions are strategic as much as scientific: does any second-generation construct differentiate enough to justify its price against a commoditizing first generation; which combinations with ADCs define the real backbone; and where do Japanese companies position, given that the Takeda-Innovent deal makes Japan a commercialization geography for the class's most-watched follower asset? This report maps each design family with named programs, the combination strategies shaping the backbone contest, the deal structures including the Japan-anchored Takeda transaction, and the follower-strategy playbook for companies entering late. It serves oncology business-development teams on both sides of the table, investors pricing the difference between generation one and generation two, and Japanese stakeholders whose options now include a direct stake in the class's next act.

Scope and Coverage

The report covers trispecific, cooperative-construct, and PD-1XIL-2 second-generation designs, incumbent follow-on and combination strategies, the Takeda-Innovent transaction and other deals, and follower playbooks, with the first-generation PD-(L)1XVEGF landscape as the reference frame.

Report Highlights

Second-generation design families: trispecifics, cooperative constructs, and PD-1XIL-2
IBI363 (TAK-928) and the Takeda-Innovent transaction (2025) anchoring Japan commercialization
Incumbent answers: Akeso follow-ons, BNT327-ADC combinations, and the Pfizer/Seagen layering
Crescent CR-001, Ottimo jankistomig, and CStone CS2009 profiled
ADC-combination strategies as the real backbone contest
Follower-strategy playbook for late entrants to the class

Product Code: JPH-109

Table of Content

1. Executive Summary

2. Second-Generation PD-(L)1 x VEGF Agents: Modality Overview and Mechanism Landscape

3. Global Pipeline and Deal Activity

4. Key Programs, Clinical Readouts, and Evidence Status

5. Japan Relevance: Trials, Approvals, and Partnerships

6. Regulatory and Pricing Considerations in Japan

7. Competitive Positioning and Valuation Considerations

8. Watch Items and Upcoming Catalysts

9. Appendix: Methodology and Sources

Companies Mentioned

Akeso (CN) - ivonescimab incumbent with next-generation bispecific and trispecific follow-ons
Summit Therapeutics (US) - ivonescimab ex-China licensee pursuing an ADC combination strategy
BioNTech (DE) - BNT327 combinations with in-house ADCs and mRNA assets
Pfizer (US) - SSGJ-707 build-out layered on the Seagen ADC base
3SBio (CN) - SSGJ-707 originator with an expanding China program
Innovent (CN) - IBI363 PD-1/IL-2a-bias originator; Takeda global partner
Takeda (JP) - option holder for IBI363 (TAK-928), IBI343, and IBI3001 with Japan-anchored commercialization via the Oct 2025 Innovent transaction
Merck & Co (US) - LM-299 follower entry from LaNova
LaNova Medicines (CN) - LM-299 originator
ImmuneOnco (CN) - IMM2510 PD-L1XVEGF originator
Instil Bio (US) - IMM2510 ex-China licensee
Crescent Biopharma (US) - CR-001 cooperative PD-1XVEGF bispecific
Ottimo Pharma (UK) - jankistomig PD-1XVEGFR2 bifunctional antibody
CStone Pharmaceuticals (CN) - CS2009 PD-1XVEGFXCTLA-4 trispecific

Product Code: JPH-109

List of Tables

Table 1. First-generation PD-(L)1XVEGF recap: the commoditization thesis
Table 2. Second-generation design taxonomy: trispecifics, cooperative constructs, and cytokine fusions
Table 3. CStone CS2009: PD-1XVEGFXCTLA-4 trispecific design and development plan
Table 4. Crescent Biopharma CR-001: cooperative PD-1XVEGF binding design
Table 5. Ottimo Pharma jankistomig: PD-1XVEGFR2 bifunctional approach
Table 6. Innovent IBI363: PD-1/IL-2 alpha-bias engineering and clinical program
Table 7. Takeda-Innovent transaction (2025): IBI363, IBI343, and IBI3001 option structure
Table 8. TAK-928 development plan under the Takeda option and Japan commercialization design
Table 9. IL-2 engineering primer: alpha-bias, beta-gamma bias, and not-alpha designs
Table 10. Competing PD-1XIL-2 and cytokine-fusion programs in global development
Table 11. Akeso follow-on constructs behind ivonescimab
Table 12. Summit Therapeutics ADC-combination strategy for ivonescimab
Table 13. BioNTech BNT327 combinations with in-house ADCs and mRNA assets
Table 14. Pfizer layering of SSGJ-707 onto the Seagen ADC base
Table 15. 3SBio expansion of the SSGJ-707 China program
Table 16. Merck & Co LM-299 follower positioning from the LaNova license (2024)
Table 17. ImmuneOnco IMM2510 and Instil Bio follower strategy
Table 18. ADC-combination rationale on PD-(L)1XVEGF backbones
Table 19. Triplet-regimen designs: bispecific backbone plus ADC plus chemotherapy
Table 20. Sequencing questions between first- and second-generation constructs
Table 21. Biomarker strategies for differentiating second-generation agents
Table 22. Safety-engineering goals for IL-2-bearing constructs
Table 23. China development environment for second-generation IO constructs
Table 24. Japan development and commercialization footprint across second-generation programs
Table 25. PMDA consultation strategy for novel trispecific and cytokine-fusion formats
Table 26. NHI pricing interaction between first- and second-generation entrants
Table 27. Japanese majors' option positions in the class beyond the Takeda transaction
Table 28. Deal and partnership activity in second-generation IO, 2024-2026
Table 29. Deal-term benchmarks for follower and second-generation licenses
Table 30. Manufacturing considerations for trispecific and fusion constructs
Table 31. Competitive-position matrix of second-generation programs
Table 32. Scenario grid for class segmentation: backbone, combination, and niche positions
Table 33. Scenario grid for the PD-1XIL-2 family against PD-(L)1XVEGF
Table 34. Scenario grid for Japan commercialization of the Takeda-optioned assets
Table 35. Follower-strategy playbook: timing, differentiation, and partner selection
Table 36. Risk register for second-generation investors
Table 37. Risk register for first-generation incumbents facing follower pressure
Table 38. Key opinion leader perspectives on construct differentiation
Table 39. Trial-design considerations for demonstrating second-generation advantage
Table 40. Watchlist of second-generation readouts and deals, 2026-2028
Table 41. Stakeholder map: originators, licensees, ADC partners, and payers
Table 42. Technology-assessment framework for multispecific constructs
Table 43. Valuation frameworks for follower-stage IO assets
Table 44. Partnering-question checklist for companies evaluating second-generation assets
Table 45. Combination-partner mapping between ADC and IO portfolios
Table 46. Historical analogies: follower strategies in checkpoint and ADC classes
Table 47. Implications of the class for Japanese IO franchise planning
Table 48. Key-question tree for oncology BD teams
Table 49. Key-question tree for investors in second-generation IO
Table 50. Timeline of second-generation PD-(L)1XVEGF and PD-1XIL-2 development, 2023-2026

List of Figures

Figure 1. First-generation commoditization thesis diagram
Figure 2. Second-generation design taxonomy map
Figure 3. CS2009 trispecific architecture
Figure 4. CR-001 cooperative binding concept
Figure 5. Jankistomig bifunctional design
Figure 6. IBI363 PD-1/IL-2 alpha-bias engineering schematic
Figure 7. Takeda-Innovent transaction structure (2025)
Figure 8. TAK-928 development and Japan commercialization plan
Figure 9. IL-2 engineering design spectrum
Figure 10. Global PD-1XIL-2 and cytokine-fusion competitive map
Figure 11. Akeso follow-on construct roadmap
Figure 12. Summit ADC-combination strategy for ivonescimab
Figure 13. BioNTech BNT327 combination architecture
Figure 14. Pfizer SSGJ-707 layering on the Seagen base
Figure 15. 3SBio China program expansion map
Figure 16. Merck LM-299 follower position
Figure 17. ImmuneOnco-Instil follower structure
Figure 18. ADC-combination rationale on bispecific backbones
Figure 19. Triplet-regimen design concepts
Figure 20. First- versus second-generation sequencing questions
Figure 21. Biomarker strategies for construct differentiation
Figure 22. Safety-engineering goals for IL-2 constructs
Figure 23. China development environment for second-generation IO
Figure 24. Japan footprint across second-generation programs
Figure 25. PMDA consultation pathway for novel formats
Figure 26. NHI pricing interaction between generations
Figure 27. Japanese majors' option map in the class
Figure 28. Second-generation deal map, 2024-2026
Figure 29. Deal-term benchmark map for follower licenses
Figure 30. Manufacturing critical path for trispecifics and fusions
Figure 31. Competitive-position matrix of second-generation programs
Figure 32. Class-segmentation scenario tree
Figure 33. PD-1XIL-2 versus PD-(L)1XVEGF scenario tree
Figure 34. Japan commercialization scenario tree for Takeda-optioned assets
Figure 35. Follower-strategy playbook schematic
Figure 36. Risk map for second-generation investors
Figure 37. Risk map for first-generation incumbents
Figure 38. KOL perspective map on construct differentiation
Figure 39. Trial-design options for demonstrating second-generation advantage
Figure 40. Second-generation readout and deal calendar, 2026-2028
Figure 41. Stakeholder map across the class
Figure 42. Multispecific technology-assessment framework
Figure 43. Follower-stage IO valuation framework
Figure 44. Partnering checklist for second-generation assets
Figure 45. ADC-IO combination-partner mapping
Figure 46. Follower-strategy analogies from checkpoint and ADC history
Figure 47. Implications map for Japanese IO franchise planning
Figure 48. Key-question tree for BD teams
Figure 49. Key-question tree for investors
Figure 50. Second-generation IO development timeline, 2023-2026

Second-Generation PD-(L)1 x VEGF Agents: Trispecifics, PD-1 x IL-2, and Follower Strategies | Oncology Modality Intelligence | US, EU5, Japan & China

Description

Table of Contents

List of Tables

Table of Content

1. Executive Summary

2. Second-Generation PD-(L)1 x VEGF Agents: Modality Overview and Mechanism Landscape

3. Global Pipeline and Deal Activity

4. Key Programs, Clinical Readouts, and Evidence Status

5. Japan Relevance: Trials, Approvals, and Partnerships

6. Regulatory and Pricing Considerations in Japan

7. Competitive Positioning and Valuation Considerations

8. Watch Items and Upcoming Catalysts

9. Appendix: Methodology and Sources

Companies Mentioned

List of Tables

List of Figures